Mosquito-borne infections Testing Market

Mosquito-borne Infections Testing Market Forecast and Outlook By FMI

In 2025, the mosquito-borne infections testing market was valued at USD 1.3 billion. Based on Future Market Insights' analysis, demand for mosquito-borne infections testing is estimated to grow to USD 1.4 billion in 2026 and USD 2.1 billion by 2036. FMI projects a CAGR of 4.7% during the forecast period.

Absolute dollar growth of USD 0.8 billion over the decade signals steady incremental expansion driven by endemic region population growth and outbreak surveillance investments rather than transformational technology shifts. Despite public health funding volatility and pricing pressure in low-resource settings, major diagnostic manufacturers sustain profitability through high-volume rapid test sales and premium molecular diagnostic placements in reference laboratories.

Summary of Mosquito-borne Infections Testing Market

• Mosquito-borne Infections Testing Market Definition:
  • The industry covers diagnostic assays and platforms for detecting mosquito-transmitted pathogens including malaria parasites and arboviruses (dengue, Zika, chikungunya).
• Demand Drivers in the Market:
  • Climate change expands vector habitats into new geographic regions.
  • Global travel trade increases imported case testing requirements.
  • Elimination programs require widespread surveillance testing.
• Key Segments Analyzed in the FMI Report:
  • Test Type: Molecular diagnostics lead with 28.0% share.
  • Indication: Malaria dominates at 35.0% share.
  • End User: Hospitals and clinics lead with 40.0% share.
• Analyst Opinion at FMI:
  • Sabyasachi Ghosh, Principal Consultant for Healthcare at Future Market Insights, opines, "In the updated version of the Mosquito-borne Infections Testing Market Report for 2026 to 2036, public health officials and diagnostic manufacturers will find insights into how multiplex platform adoption is reshaping laboratory workflows and how climate change modeling is informing strategic capacity planning. Besides this, my findings point at pricing pressure in malaria-endemic markets directly impacting rapid test margins and the shift toward integrated surveillance platforms combining diagnostic data with epidemiological tracking."
• Strategic Implications/Executive Takeaways:
  • Shift focus from single-pathogen tests to multiplex platforms.
  • Treat pricing sustainability as market access requirement for endemic regions.
  • Prioritize connectivity-enabled tests for real-time surveillance integration.
• Methodology:
  • Validated through WHO procurement data and manufacturer shipment records.
  • Zero reliance on speculative third-party market research reports.
  • Based on verifiable disease burden statistics and national testing volume data.

As Peter Schultz, PhD, Chief Executive Officer of Calibr and Scripps Research, noted regarding the urgency of outbreak prevention, “Insect-borne infectious diseases remain primary causes of severe illnesses and fatalities worldwide, and new approaches to preventing outbreaks of these diseases are critically needed.” [1]

China (6.5% CAGR) and India (6.0% CAGR) drive new opportunities through expanding healthcare infrastructure and government surveillance programs. Brazil (5.0% CAGR) contributes via endemic disease burden and public health system investments. Mature testing markets such as Germany (5.5%), the United States (4.4%), the United Kingdom (3.9%), and Japan (3.4%) generate replacement demand through technology upgrades, with volume expansion constrained by low endemicity and reliance on travel-related testing.

Mosquito-borne Infections Testing Market Definition

Mosquito-borne infections testing comprises diagnostic assays and platforms designed to detect pathogens transmitted by mosquito vectors, including parasites (Plasmodium species causing malaria), viruses (dengue, Zika, chikungunya, West Nile, yellow fever), and associated immunological responses. These tests utilize molecular, serological, and rapid diagnostic technologies to identify active infections, support clinical management, enable outbreak surveillance, and guide public health interventions across endemic and non-endemic regions.

Mosquito-borne Infections Testing Market Inclusions

The report includes a comprehensive analysis of market dynamics, featuring Global and Regional Market Sizes (Volume and Value) and a 10-year Forecast (2026-2036). It covers segmental breakdowns by test type (Molecular Diagnostics, Immunoassay Systems, ELISA, Rapid Tests, Blot Systems, Microspot Array Diagnostics), indication (Malaria, Zika, Chikungunya, Dengue, Others), end user (Hospitals and Clinics, Private Commercial Laboratories, Academic and Research Centers), and geographic regions.

Mosquito-borne Infections Testing Market Exclusions

The scope excludes vector surveillance products not used for human diagnostics, insecticides and vector control products, and therapeutic pharmaceuticals for mosquito-borne infections. It also omits veterinary testing for animal arboviruses, focusing strictly on human diagnostic applications for mosquito-transmitted pathogens.

Mosquito-borne Infections Testing Market Research Methodology

• Primary Research: Interviews were conducted with diagnostic manufacturers, reference laboratory directors, hospital infectious disease specialists, and public health officials across major regions. Epidemiologists clarified disease surveillance requirements.
• Desk Research: WHO disease burden data, national surveillance statistics, and corporate financial filings supported volume benchmarking.
• Market-Sizing and Forecasting: A hybrid top-down and bottom-up model was developed. Demand was reconstructed from global malaria testing volumes, dengue incidence data, and outbreak surveillance testing requirements, then validated against manufacturer shipment data and procurement records.
• Data Validation and Update Cycle: Outputs undergo anomaly screening, variance checks across production and trade datasets, and structured peer review prior to release.

Segmental Analysis

Mosquito-borne Infections Testing Market Analysis by Test Type

Based on FMI’s mosquito-borne infections testing market report, molecular diagnostics is estimated to hold a 28.0% share in 2026. The shift toward molecular methods is driven by the need for early detection during the viremic phase, where antibody tests often fail, pushing labs and frontline settings toward automated, high-throughput workflows and targeted multiplex capability.

• Point-of-Care Molecular Expansion: "In January 2026, Cepheid announced that it had received FDA clearance for its Xpert GI Panel, continuing its expansion of the GeneXpert system which supports broad detection of pathogens including high-priority infectious diseases." [2]
• Malaria Molecular Surveillance: "Abbott and its partner organizations are joining forces with local government to end malaria for good, with Abbott contributing to the partnership by helping to design community health worker training on the use of rapid diagnostic tests and the data collection from those tests." [3]
• Early-Window Advantage: Molecular assays are increasingly adopted where programs prioritize early rule-in confidence and faster escalation decisions, especially in outbreak-prone geographies with repeated seasonal exposure.

Mosquito-borne Infections Testing Market Analysis by Indication

Based on FMI’s mosquito-borne infections testing market report, malaria testing is estimated to hold a 35.0% share in 2026. While rapid tests provide the volume, value capture is shifting toward higher-information workflows and multiplexed kits that help differentiate co-endemic infections in clinically similar febrile presentations.

• Rapid Test Volume Leadership: "Investments in laboratories, oxygen provision and supply chains save lives and reinforce health security. The Results achieved demonstrate the strength of the Global Fund model, and underscore why investing in this unique partnership is one of the most effective ways to save lives." [4]
• Multiplex Innovation: "In April 2025, QIAGEN announced the launch of the QIAprep Plasmodium Kit and two companion assays to support malaria research and surveillance efforts, combining sample preparation and quantitative PCR (qPCR) into a single workflow." [5]
• Differentiation Premium: Buyers increasingly prioritize tests that reduce misclassification risk across co-circulating mosquito-borne diseases, lifting demand for higher-performance assays even when RDTs remain the throughput backbone.

Mosquito-borne Infections Testing Market Drivers, Restraints, and Opportunities

Future Market Insights analysis suggests that historical patterns point to a mature, public-health anchored diagnostics market where testing volume is structurally tied to seasonality, outbreak cycles, and government procurement rather than discretionary consumer demand. Estimated valuation in 2026 reflects an immediate "preparedness push" as health systems expand surveillance coverage and laboratory capacity to reduce time-to-detection and prevent downstream hospitalization costs during dengue, malaria, and other mosquito-borne outbreaks.

While rapid diagnostic tests continue to drive throughput, value growth increasingly comes from molecular and multiplex workflows that improve early-window detection and help clinicians differentiate co-endemic febrile illnesses. The forecast assumes a "new normal" where buyers prioritize total system reliability, data reporting, and supply continuity, with growth aligned to sustained vector control funding and routine screening programs.

• Automation and Multiplex Upgrading: Demand shifts toward high-throughput molecular platforms and multiplex panels that compress turnaround time and improve clinical confidence in the early phase of infection.
• Access and Compliance Constraints: Restraints come from limited lab infrastructure in high-burden regions, reimbursement variability, and regulatory requirements that slow adoption of new assays.
• Surveillance-Linked Expansion: Opportunity rises where testing integrates with digital reporting and community deployment models, enabling faster outbreak signals, targeted interventions, and repeat procurement tied to measurable public-health outcomes.

Regional Analysis

Based on the regional analysis, mosquito-borne infections testing market is segmented into Africa, South Asia, Southeast Asia, Latin America, Europe, and North America across 40+ countries. The full report also offers market attractiveness analysis based on regional trends.

Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research

North America Mosquito-borne Infections Testing Market Analysis

North America is characterized by travel medicine demand, imported case management, and rising alertness to localized transmission, which increases the need for rapid confirmation testing and public health surveillance support.

• United States: Demand for mosquito-borne infections testing in the United States is projected to rise at a 4.4% CAGR through 2036. Growth is increasingly tied to locally acquired cases, where local dengue transmission was reported in 2024 in California, Florida, and Texas, and Florida also reported local dengue transmission in 2025 [6]

FMI’s report includes a detailed analysis of the growth in the North American region, along with a country-wise assessment that includes the USA and Canada. Readers can also find regional trends, regulations, and market growth based on different segments and countries in the North America region.

South Asia Mosquito-borne Infections Testing Market Analysis

South Asia, led by India, is characterized by a dual-burden dynamic where endemic malaria coincides with increasingly severe seasonal dengue outbreaks, raising the value of differentiated kits that help clinicians and surveillance teams separate co-circulating febrile illnesses.

• India: Domestic demand is accelerating at a 6.0% CAGR through 2036, supported by expanding surveillance and the rising threat of multiple arboviruses, where dengue and chikungunya incidence has been rising and dengue, chikungunya, and Japanese encephalitis are cited as emerging threats alongside malaria [7]

The full report analyze the mosquito-borne infections testing market across South Asia from 2021-2036, covering disease surveillance trends, testing adoption, and growth drivers in India and other South Asian countries. The assessment highlights trends that dictate test mix, procurement, and reporting practices.

Latin America Mosquito-borne Infections Testing Market Analysis

Latin America is a critical market for arbovirus diagnostics, where dengue volume and re-emerging outbreaks increase decentralized testing needs across public health networks and local laboratories.

• Brazil: A projected 5.0% CAGR through 2036 is supported by sustained dengue burden, where Brazil reported 1,660,190 probable dengue cases as of 26 Dec 2025 and accounted for approximately 87% of all reported cases in the Americas [8]

The report consists of a detailed analysis for the market in Brazil, Mexico, Argentina, Colombia, Peru and Rest of Latin America. Readers can find detailed information about several factors, such as surveillance intensity, testing access, and public health procurement trends impacting growth in Latin America.

Europe Mosquito-borne Infections Testing Market Analysis

Europe is driven by travel-linked case management and high-tech surveillance, where testing demand concentrates around returning travelers, imported case monitoring, and public health lab confirmation workflows.

• Germany: Demand is projected to rise at a 5.5% CAGR through 2036, where returning-traveler surveillance remains central and 2,079 German travelers with dengue infection returning from abroad were registered between September 2023 and December 2024 [9]

FMI’s analysis of the mosquito-borne infections testing market in Europe consists of country-wise assessment that includes Germany, the UK, France, Italy, Spain, Nordics, Benelux and Rest of Europe. Readers can know various surveillance practices, reporting structures, and evolving regional testing trends.

Competitive Aligners for Market Players

Market structure remains fragmented overall, yet practical competition is concentrated among a limited set of suppliers capable of meeting volume, regulatory, and operational expectations of national malaria programs, large hospital networks, and reference laboratories. A meaningful share of market value sits with manufacturers that can supply both rapid diagnostic tests and higher-complexity molecular workflows, while smaller players compete on single-disease kits with limited pricing leverage and higher demand volatility during non-outbreak periods. The primary competitive variable is not peak margin capture, but tender win-rate driven by proof of performance, quality consistency, and reliable delivery under surge conditions.

Producers with integrated manufacturing, validated quality systems, and multi-region regulatory clearances absorb raw material and logistics shocks more effectively and maintain continuity during outbreak spikes. Suppliers without scale rely on third-party manufacturing or constrained distribution, increasing exposure to stock-outs, batch variability, and requalification risk with public health buyers. Compliance capability further narrows the field. Ability to meet WHO-related procurement expectations, national regulatory requirements, and post-market surveillance obligations demands strong clinical evidence packages and traceable lot control, creating attrition among underinvested vendors.

Customer concentration reinforces buyer leverage. Large donors and ministries dual-source to avoid dependency, compressing pricing power and elevating service, training, connectivity, and reporting support as differentiators.

Recent Developments

The report includes full coverage of key trends from competitive benchmarking. Some of the recent developments covered in the reports:

• In October 2025, Roche received CE mark approval for its automated Elecsys Dengue Ag test, delivering results in 18 minutes and enabling faster, reliable dengue diagnosis during outbreaks worldwide [10].
• In June 2025, bioMérieux agreed to acquire Day Zero Diagnostics’ sequencing assets for under USD 25 million, strengthening its rapid infectious disease testing pipeline and advancing next-generation diagnostics for antibiotic-resistant infections [11].

Key Players in Mosquito-borne Infections Testing Market

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• Qiagen N.V.
• Thermo Fisher Scientific Inc.
• Cepheid (Danaher Corporation)
• DiaSorin S.p.A.
• Hologic, Inc.
• Meridian Bioscience, Inc.
• bioMérieux SA
• QuidelOrtho Corporation
• Beckman Coulter, Inc. (Danaher Corporation)
• BD (Becton, Dickinson and Company)
• PerkinElmer, Inc.
• Grifols S.A.
• Oxford Immunotec International
• Trinity Biotech plc

Scope of the Report

Mosquito-borne Infections Testing Market Analysis by Segments

Test Type:

• Molecular Diagnostics
  • PCR (Polymerase Chain Reaction)
  • RT-PCR (Real-Time PCR)
  • Isothermal Amplification
  • Next-Generation Sequencing
• Immunoassay Systems
  • Chemiluminescence Immunoassay
  • Fluorescence Immunoassay
• ELISA (Enzyme-Linked Immunosorbent Assay)
• Rapid Tests
  • Rapid Diagnostic Tests (RDTs)
  • Lateral Flow Assays
• Blot Systems and Evaluation Software
• Microspot Array Diagnostics

Indication:

• Malaria
  • Plasmodium falciparum
  • Plasmodium vivax
  • Mixed/Other Species
• Zika Virus
• Chikungunya
• Dengue
  • Dengue NS1 Antigen
  • Dengue IgM/IgG Antibodies
• Others (West Nile, Yellow Fever, Japanese Encephalitis)

End User:

• Hospitals and Clinics
  • Infectious Disease Departments
  • Emergency Departments
  • Outpatient Clinics
• Private Commercial Laboratories
  • Reference Laboratories
  • Regional Diagnostic Centers
• Academic and Research Centers
  • Universities
  • Research Institutes
• Others
  • Blood Banks
  • Public Health Laboratories
  • Travel Medicine Centers

Region:

• North America
  • United States
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Argentina
  • Colombia
  • Peru
  • Rest of Latin America
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Rest of Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia & Pacific
  • India
  • Bangladesh
  • Sri Lanka
  • Pakistan
  • Nepal
  • Rest of South Asia
• Southeast Asia
  • Indonesia
  • Thailand
  • Vietnam
  • Malaysia
  • Philippines
  • Rest of Southeast Asia
• Oceania
  • Australia
  • New Zealand
  • Pacific Islands
• Middle East & Africa
  • Nigeria
  • Kenya
  • Ghana
  • Tanzania
  • Uganda
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East & Africa

Bibliography

• [1] Lab Manager. (2025). Well-known animal health drug could stop outbreaks of malaria and Zika virus. Lab Manager.
• [2] Cepheid. (2026, January 20). Cepheid receives FDA clearance for Xpert® GI Panel to support broad detection of gastrointestinal pathogens. Cepheid Press Release.
• [3] Abbott Laboratories. (2025). Joining together to end malaria. Abbott USA
• [4] [Corporate Author Unknown]. (2025). Core 2025 results report (PDF).
• [5] QIAGEN N.V. (2025). QIAGEN launches QIAprep® Plasmodium Kit to strengthen malaria research and surveillance efforts. QIAGEN Press Release.
• [6] Centers for Disease Control and Prevention (CDC). (2025). Current dengue outbreak. CDC.
• [7] National Health Mission (NHM) Mizoram. (2025). Official website. Government of Mizoram.
• [8] BEACON Consortium. (2025). BEACON initiative overview.
• [9] PubMed. (2024). Dengue virus infection in travellers after dengue vaccination, Germany 2023-24. PubMed.
• [10] Roche Diagnostics. (2025). Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue. Roche Press Release.
• [11] bioMérieux. (2025). bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies. bioMérieux Press Release.

This Report Addresses

• Market intelligence to enable structured strategic decision-making across endemic and non-endemic testing markets
• Market size estimation and 10-year revenue forecasts from 2026 to 2036, supported by validated disease burden data and testing volume statistics
• Growth opportunity mapping across test types, indications, and end-user segments with emphasis on molecular diagnostics and multiplex platforms
• Segment and regional revenue forecasts covering malaria, dengue, Zika, chikungunya, and other mosquito-borne infections
• Competition strategy assessment including product portfolio breadth, regulatory qualification status, and procurement channel access benchmarking
• Technology roadmap tracking including point-of-care molecular platforms, multiplex assay development, and connectivity-enabled diagnostics
• Regulatory impact analysis covering WHO prequalification, CE marking, FDA clearance, and country-level registration requirements
• Market report delivery in PDF, Excel, PPT, and interactive dashboard formats for executive and operational use